ArticleTechnology in cancer research & treatment

A Randomized Phase III Study of Anlotinib Versus Bevacizumab in Combination With CAPEOX as First-Line Therapy for

Jinjie He et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.